• Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals 

      Hovland, Anders; Nestvold, Torunn Kristin; Bohov, Pavol; Trøseid, Marius; Aukrust, Pål; Berge, Rolf Kristian; Nielsen, Erik Waage; Retterstøl, Kjetil; Lappegård, Knut Tore (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-25)
      Background: <br> Obesity is a global pandemic leading to increased mortality and increased risk of cardiovascular disease. Bariatric surgery is an established treatment of obesity leading to weight loss and reduction of mortality. To further elucidate how bariatric surgery improves metabolic control, we explored the fatty acid (FA) profiles in morbidly obese subjects treated with lifestyle ...
    • The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection 

      Trøseid, Marius; Mayerhofer, Christiane Caroline; Broch, Kaspar; Arora, Satish; Svardal, Asbjørn M.; Hov, Johannes Espolin Roksund; Andreassen, Arne K.; Gude, Einar; Karason, Kristjan; Dellgren, Gøran; Berge, Rolf Kristian; Gullestad, Lars; Aukrust, Pål; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-06-19)
      <p><i>BACKGROUND - </i>Alterations in the partly microbiota-dependent carnitine–γ-butyrobetaine (γBB)–trimethylamine N-oxide (TMAO) pathway have been linked to the progression of heart failure and atherosclerotic disease. We evaluated if circulating γBB, TMAO, and their common precursors carnitine and trimethyllysine (TML) were dysregulated after heart transplantation and associated with development ...
    • Gut microbiota-dependent trimethylamine N-oxide associates with inflammation in common variable immunodeficiency 

      Macpherson, Magnhild Eide; Hov, Johannes Espolin Roksund; Ueland, Thor; Dahl, Tuva Børresdatter; Kummen, Martin; Otterdal, Kari; Holm, Kristian; Berge, Rolf Kristian; Mollnes, Tom Eirik; Trøseid, Marius; Halvorsen, Bente; Aukrust, Pål; Fevang, Børre; Jørgensen, Silje Fjellgård (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-16)
      A substantial proportion of patients with common variable immunodeficiency (CVID) have inflammatory and autoimmune complications of unknown etiology. We have previously shown that systemic inflammation in CVID correlates with their gut microbial dysbiosis. The gut microbiota dependent metabolite trimethylamine N-oxide (TMAO) has been linked to several metabolic and inflammatory disorders, but has ...
    • Impaired HDL function amplifies systemic inflammation in common variable immunodeficiency 

      Macpherson, Magnhild Eide; Halvorsen, Bente; Yndestad, Arne; Ueland, Thor; Mollnes, Tom Eirik; Berge, Rolf Kristian; Rashidi, Azita; Otterdal, Kari; Gregersen, Ida; Kong, Xiang Yi; Holven, Kirsten Bjørklund; Aukrust, Pål; Fevang, Børre; Jørgensen, Silje Fjellgård (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-07-01)
      Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency, characterized by inadequate antibody responses and recurrent bacterial infections. Paradoxically, a majority of CVID patients have non-infectious inflammatory and autoimmune complications, associated with systemic immune activation. Our aim was to explore if HDL, known to have anti-inflammatory properties, ...
    • Major increase in microbiota-dependent proatherogenic metabolite TMAO one year after bariatric surgery 

      Trøseid, Marius; Hov, Johannes Espolin Roksund; Nestvold, Torunn Kristin; Thoresen, Hanne; Berge, Rolf Kristian; Svardal, Asbjørn M.; Lappegård, Knut Tore (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-04-15)
      Background: Trimethylamine-N-oxide (TMAO) is formed in the liver from trimethylamine (TMA), a product exclusively generated by the gut microbiota from dietary phosphatidylcholine and carnitine. An alternative pathway of TMAO formation from carnitine is via the microbiota-dependent intermediate g-butyrobetaine (gBB). Elevated TMAO levels are associated with cardiovascular disease (CVD), but little ...
    • Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency 

      Jørgensen, Silje Fjellgård; Macpherson, Magnhild Eide; Bjørnetrø, Tonje; Holm, Kristian; Kummen, Martin; Rashidi, Azita; Michelsen, Annika; Lekva, Tove; Halvorsen, Bente; Trøseid, Marius; Mollnes, Tom Eirik; Berge, Rolf Kristian; Yndestad, Arne; Ueland, Thor; Karlsen, Tom Hemming; Aukrust, Pål; Hov, Johannes Espolin Roksund; Fevang, Børre (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-17)
      Common variable immunodeficiency (CVID) patients have reduced gut microbial diversity compared to healthy controls. The reduced diversity is associated with gut leakage, increased systemic inflammation and ten “key” bacteria that capture the gut dysbiosis (dysbiosis index) in CVID. Rifaximin is a broad-spectrum non-absorbable antibiotic known to reduce gut leakage (lipopolysaccharides, LPS) in liver ...
    • Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial 

      Awoyemi, Ayodeji Olawale; Mayerhofer, Cristiane; Felix, Alex S.; Hov, Johannes Espolin Roksund; Moscavitch, Samuel D.; Lappegård, Knut Tore; Hovland, Anders; Halvorsen, Sigrun; Halvorsen, Bente; Gregersen, Ida; Svardal, Asbjørn M.; Berge, Rolf Kristian; Hansen, Simen Hyll; Götz, Alexandra; Holm, Kristian; Aukrust, Pål; Åkra, Sissel; Seljeflot, Ingebjørg; Solheim, Svein; Lorenzo, Andrea; Gullestad, Lars; Trøseid, Marius; Broch, Kaspar (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-28)
      Background - The gut microbiota represents a potential treatment target in heart failure (HF) through microbial metabolites such as trimethylamine N-oxide (TMAO) and systemic inflammation. Treatment with the probiotic yeast Saccharomyces boulardii have been suggested to improve left ventricular ejection fraction (LVEF).<p> <p>Methods - In a multicentre, prospective randomized open label, blinded ...
    • Rosuvastatin alters the genetic composition of the human gut microbiome 

      Kummen, Martin; Solberg, Ole Geir; Larsen, Christopher Storm; Holm, Kristian; Ragnarsson, Asgrimur; Trøseid, Marius; Vestad, Beate; Skårdal, Rita; Yndestad, Arne; Ueland, Thor; Svardal, Asbjørn M.; Berge, Rolf Kristian; Seljeflot, Ingebjørg; Gullestad, Lars; Karlsen, Tom Hemming; Aaberge, Lars; Aukrust, Pål; Hov, Johannes Espolin Roksund (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-25)
      The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the human microbiome is scarce. We aimed to characterize the effect of rosuvastatin on gut microbiome composition and inferred genetic content in stool samples from a randomized controlled ...